Daewoong Pharmaceutical Company is Drug Discovery in South Korea that focus on Pharmaceutical Co Ltd business. Founded in 1945. They cover business area such as Daewoong Pharmaceutical Co Ltd, manufacture, prescription drug product, Moxicle, Plunazol Cap, Bearcef tab, brand, Ursa, Nabota, Luphere, Easyef, Cretropin, manufacturing facility, Hyangnam, Sungnam.
1945
( 79 years old in 2024 )
Pharmaceutical Co Ltd
-
12, Bongeunsa-ro 114-gil
Daewoong Pharmaceutical Building, Gangnam-gu
Seoul
South Korea
Private
Daewoong Pharmaceutical Co Ltdmanufactureprescription drug productMoxiclePlunazol CapBearcef tabbrandUrsaNabotaLuphereEasyefCretropinmanufacturing facilityHyangnamSungnam
* We use standard office opening hours in near Daewoong Pharmaceutical Company's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Daewoong Pharmaceutical Company is Drug Discovery business from South Korea that founded in 1945 (79 years old in 2024), Daewoong Pharmaceutical Company business is focusing on Pharmaceutical Co Ltd.
Daewoong Pharmaceutical Company headquarter office and corporate office address is located in 12, Bongeunsa-ro 114-gil Daewoong Pharmaceutical Building, Gangnam-gu Seoul South Korea.
Daewoong Pharmaceutical Company was founded in South Korea.
In 2024, Daewoong Pharmaceutical Company is currently focus on Pharmaceutical Co Ltd sector.
Above is snippet of Google Trends for "Pharmaceutical Co Ltd" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Daewoong Pharmaceutical Company, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
